Literature DB >> 24614841

Occupational status among adult survivors following allo-SCT.

J Winterling1, E Johansson2, A Wennman-Larsen3, L-M Petersson4, P Ljungman5, K Alexanderson4.   

Abstract

Being in work or the equivalent is an important goal after allo-SCT and is used as an indicator of recovery. The aim was to elucidate occupational status and factors associated with work among SCT survivors. Adults in working age with a haematological disease (n=177) were followed up within a median of 8 (range 28) years post allo-SCT. Predictors of not being in work at all or working part-time because of sick leave, disability pension or early old-age pension were analyzed using logistic regression analyses. At diagnosis, 82% of the participants were working full-time and 2% were on sick leave or old-age pension. At follow-up, 52% were working full-time, 27% were working part-time and 17% were on sick leave, disability pension or old-age pension. Not working at all was associated with multi-morbidity (P=0.01) and poorer health (P=0.00). Working part-time was associated with a higher age at diagnosis (P=0.00), being a woman (P=0.03), being born abroad (P=0.03) and multi-morbidity (P=0.00). In conclusion, the majority of survivors were in paid work at follow-up; however, a substantial number were not working or worked part-time.

Entities:  

Mesh:

Year:  2014        PMID: 24614841     DOI: 10.1038/bmt.2014.26

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  39 in total

Review 1.  Assessing the impact of cancer on work outcomes: what are the research needs?

Authors:  John F Steiner; Tia A Cavender; Deborah S Main; Cathy J Bradley
Journal:  Cancer       Date:  2004-10-15       Impact factor: 6.860

2.  A qualitative study of work and work return in cancer survivors.

Authors:  Deborah S Main; Carolyn T Nowels; Tia A Cavender; Martine Etschmaier; John F Steiner
Journal:  Psychooncology       Date:  2005-11       Impact factor: 3.894

Review 3.  Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30.

Authors:  N Grulke; C Albani; H Bailer
Journal:  Bone Marrow Transplant       Date:  2011-05-23       Impact factor: 5.483

4.  Long-term outcome after marrow transplantation for severe aplastic anemia.

Authors:  H J Deeg; W Leisenring; R Storb; J Nims; M E Flowers; R P Witherspoon; J Sanders; K M Sullivan
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

Review 5.  Factors reported to influence the return to work of cancer survivors: a literature review.

Authors:  Evelien R Spelten; Mirjam A G Sprangers; Jos H A M Verbeek
Journal:  Psychooncology       Date:  2002 Mar-Apr       Impact factor: 3.894

Review 6.  Interventions to enhance return-to-work for cancer patients.

Authors:  Angela Gem de Boer; Taina Taskila; Sietske J Tamminga; Monique Hw Frings-Dresen; Michael Feuerstein; Jos H Verbeek
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

7.  Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors.

Authors:  J M Hows; J R Passweg; A Tichelli; A Locasciulli; R Szydlo; A Bacigalupo; N Jacobson; P Ljungman; J Cornish; A Nunn; B Bradley; G Socié
Journal:  Bone Marrow Transplant       Date:  2006-10-30       Impact factor: 5.483

Review 8.  Factors affecting cancer survivors' employment and work ability.

Authors:  T Taskila; M L Lindbohm
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

9.  What things are important in people's lives? A survey of the public's judgements to inform scales of health related quality of life.

Authors:  A Bowling
Journal:  Soc Sci Med       Date:  1995-11       Impact factor: 4.634

10.  Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma.

Authors:  Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry Storer; Jean E Sanders; Mary E D Flowers; Paul J Martin
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

View more
  10 in total

1.  Health-Related Quality of Life and Personal Life Goals of Adults With Sickle Cell Disease After Hematopoietic Stem Cell Transplantation.

Authors:  Agatha M Gallo; Crystal Patil; Tokunbo Adeniyi; Lewis L Hsu; Damiano Rondelli; Santosh Saraf
Journal:  West J Nurs Res       Date:  2018-04-06       Impact factor: 1.967

Review 2.  Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care.

Authors:  Minoo Battiwalla; André Tichelli; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-03       Impact factor: 5.742

3.  Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey.

Authors:  Rachel B Salit; Stephanie J Lee; Linda J Burns; Bronwen E Shaw; Navneet S Majhail; Neel S Bhatt; William A Wood; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2020-04-29       Impact factor: 5.742

4.  Inability to work and need for disability pension among long-term survivors of hematopoietic stem cell transplantation.

Authors:  A Tichelli; S Gerull; A Holbro; A Buser; G Nair; M Medinger; D Heim; J P Halter; J R Passweg
Journal:  Bone Marrow Transplant       Date:  2017-06-26       Impact factor: 5.483

5.  General health, symptom occurrence, and self-efficacy in adult survivors after allogeneic hematopoietic stem cell transplantation: a cross-sectional comparison between hospital care and home care.

Authors:  Karin Bergkvist; Jeanette Winterling; Eva Johansson; Unn-Britt Johansson; Britt-Marie Svahn; Mats Remberger; Jonas Mattsson; Joacim Larsen
Journal:  Support Care Cancer       Date:  2014-10-17       Impact factor: 3.603

6.  Psychosocial and financial issues after hematopoietic cell transplantation.

Authors:  David Buchbinder; Nandita Khera
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

7.  Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.

Authors:  Neel S Bhatt; Ruta Brazauskas; Rachel B Salit; Karen Syrjala; Stephanie Bo-Subait; Heather Tecca; Sherif M Badawy; K Scott Baker; Amer Beitinjaneh; Nelli Bejanyan; Michael Byrne; Ajoy Dias; Nosha Farhadfar; César O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Robert J Hayashi; Sanghee Hong; Yoshihiro Inamoto; Kareem Jamani; Kimberly A Kasow; Nandita Khera; Maxwell M Krem; Hillard M Lazarus; Catherine J Lee; Stephanie Lee; Navneet S Majhail; Adriana K Malone; David I Marks; Lih-Wen Mau; Samantha J Mayo; Lori S Muffly; Sunita Nathan; Taiga Nishihori; Kristin M Page; Jaime Preussler; Hemalatha G Rangarajan; Seth J Rotz; Nina Salooja; Bipin N Savani; Raquel Schears; Tal Schechter-Finkelstein; Gary Schiller; Ami J Shah; Akshay Sharma; Trent Wang; Baldeep Wirk; Minoo Battiwalla; Hélène Schoemans; Betty Hamilton; David Buchbinder; Rachel Phelan; Bronwen Shaw
Journal:  Transplant Cell Ther       Date:  2021-04-22

8.  Factors influencing life satisfaction in acute myeloid leukemia survivors following allogeneic stem cell transplantation: a cross-sectional study.

Authors:  Susanne Amler; Maria Cristina Sauerland; Christian Deiters; Thomas Büchner; Andrea Schumacher
Journal:  Health Qual Life Outcomes       Date:  2015-02-27       Impact factor: 3.186

9.  Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?

Authors:  Arwen Stikvoort; Mikael Sundin; Mehmet Uzunel; Jens Gertow; Berit Sundberg; Marie Schaffer; Jonas Mattsson; Michael Uhlin
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

10.  Important factors associated with sick leave after allogeneic haematopoietic stem cell transplantation-a 1-year prospective study.

Authors:  Linda Eriksson; Agneta Wennman-Larsen; Karin Bergkvist; Per Ljungman; Jeanette Winterling
Journal:  J Cancer Surviv       Date:  2021-01-08       Impact factor: 4.442

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.